SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 27, 2001
SALIX PHARMACEUTICALS, LTD.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
British Virgin Islands
--------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
---------------------------------- ----------------------------------
(Commission file Number) (IRS Employer ID Number)
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
- ------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(919) 862-1000
- ------------------------------------------------------------------------------
Registrant's telephone number, including area code
Item 5. Other Events
On December 27, 2001, Salix issued a press release to announce the filing
with the U. S. Food and Drug Administration of a new drug application for
rifaximin.
A copy of this press release is attached as an exhibit.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: December 27, 2001
/s/ Adam C. Derbyshire
-----------------------------------
Adam C. Derbyshire, Vice President
and Chief Financial Officer